Clinical Data Drives Strategic Decisions: Oruka, Boehringer, and Astellas Navigate Risk and Opportunity. Recent trial readouts highlight how clinical outcomes—positive and negative—are shaping portfolio decisions and competitive positioning.

Gene editing delivers first clinical proof of viral reservoir elimination, raising genuine prospects of cure for chronic hepatitis B. Obesity and metabolic liver disease pipelines continue to mature, with durable data supporting next-generation agents. Enterprise AI deployment accelerates across pharma. Vaccine development resurges as a strategic priority. Regulatory divergence between the FDA and EMA remains a recurring feature of the week.

AI integration moves from experimentation to enterprise-wide deployment. Clinical readouts reinforce the difficulty of beating established immunotherapy standards, while positive data in infection, rare disease & metabolic disease highlight ongoing unmet need. A meaningful regulatory approval addresses treatment-resistant hypertension. Biosimilar launches continue to erode branded franchises. Across the week, the gap between scientific promise and commercial reality remains a

In this week’s Pharma Phriday (May 15, 2026): A landmark week. The first tau-directed therapy to show cognitive benefit in Alzheimer's disease. A pivotal gene therapy milestone in DMD. The largest China-originated licensing deal ever announced. A new BCL2 inhibitor class approved a decade after the last. And AI attracting record funding and embedding itself at every layer of drug discovery.

Pharma Phriday (May 1, 2026): A week of bold dealmaking and standout clinical milestones, including a landmark gene-editing readout. AI momentum continued with another high-value partnership. Regulators delivered unusually wide-ranging decisions, including a serious alleged trial-fraud case. Major acquisitions reshaped rare disease, oncology and neuroscience, alongside UK reform and early sales data for a new obesity drug.

This week’s Pharma Phriday (April 24, 2026) covers major AI platform launches and enterprise partnerships, showing AI is expanding beyond drug discovery into wider roles. Clinical trials in respiratory, haematology, and neurology had mixed results, while regulators approved products in vaccines, immunology, oncology, and infectious disease. The industry saw notable consolidation with several multi-billion dollar acquisitions in gene therapy, regenerative medicine, and biosimi

In this week’s Pharma Phriday (April 17, 2026): In the clinic, some of the hardest-to-treat cancers are finally yielding ground, with survival data that would have been difficult to imagine a few years ago. Rare and underserved oncology and dermatology indications are also seeing regulatory progress. On the deals side, ADCs continue to attract serious investment, AI partnerships are expanding well beyond drug discovery into core business operations, and radiopharma is drawing